VEGFR1–mediated pericyte ablation links VEGF and PlGF to cancer-associated retinopathy
暂无分享,去创建一个
Zhen-ping Zhu | Yihai Cao | S. Dissing | E. Hedlund | R. Cao | Yuan Xue | K. Tritsaris | F. Lucchini | Z. Zhong | B. Tondelli
[1] H. Augustin,et al. Fulvene-5 potently inhibits NADPH oxidase 4 and blocks the growth of endothelial tumors in mice. , 2009, The Journal of clinical investigation.
[2] Yihai Cao. Positive and Negative Modulation of Angiogenesis by VEGFR1 Ligands , 2009, Science Signaling.
[3] Christian Fischer,et al. FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? , 2008, Nature Reviews Cancer.
[4] A. Hansen,et al. Anti-VEGF agents confer survival advantages to tumor-bearing mice by improving cancer-associated systemic syndrome , 2008, Proceedings of the National Academy of Sciences.
[5] Magali Saint-Geniez,et al. Endogenous VEGF Is Required for Visual Function: Evidence for a Survival Role on Müller Cells and Photoreceptors , 2008, PloS one.
[6] M. Matsumura,et al. Role of soluble vascular endothelial growth factor receptor-1 in the vitreous in proliferative diabetic retinopathy. , 2008, Ophthalmology.
[7] Jianhua Huang,et al. A Role for VEGF as a Negative Regulator of Pericyte Function and Vessel Maturation , 2008, Nature.
[8] B. Perry,et al. Tris (Dibenzylideneacetone) Dipalladium, a N-Myristoyltransferase-1 Inhibitor, Is Effective against Melanoma Growth In vitro and In vivo , 2008, Clinical Cancer Research.
[9] K. Becker,et al. VEGF-B inhibits apoptosis via VEGFR-1-mediated suppression of the expression of BH3-only protein genes in mice and rats. , 2008, The Journal of clinical investigation.
[10] M. Giacca,et al. Anti-PlGF Inhibits Growth of VEGF(R)-Inhibitor-Resistant Tumors without Affecting Healthy Vessels , 2007, Cell.
[11] C. Focan,et al. [Cancer associated retinopathy (CAR). Two clinical cases and review of the literature]. , 2007, Revue medicale de Liege.
[12] R. Steinbrook,et al. The price of sight--ranibizumab, bevacizumab, and the treatment of macular degeneration. , 2006, The New England journal of medicine.
[13] E. Stone. A very effective treatment for neovascular macular degeneration. , 2006, The New England journal of medicine.
[14] J. Martin Collinson,et al. Corneal avascularity is due to soluble VEGF receptor-1 , 2006, Nature.
[15] A. Hansen,et al. Hepatocyte growth factor is a lymphangiogenic factor with an indirect mechanism of action. , 2006, Blood.
[16] C. Foster,et al. Cancer Associated Retinopathy (CAR): An Autoimmune-Mediated Paraneoplastic Syndrome , 2006, Seminars in ophthalmology.
[17] I. Zachary. Neuroprotective Role of Vascular Endothelial Growth Factor: Signalling Mechanisms, Biological Function, and Therapeutic Potential , 2005, Neurosignals.
[18] Jean-Michel Foidart,et al. Pegaptanib and age-related macular degeneration. , 2005, The New England journal of medicine.
[19] E. Gragoudas,et al. Pegaptanib for neovascular age-related macular degeneration. , 2004, The New England journal of medicine.
[20] N. Ferrara,et al. The biology of VEGF and its receptors , 2003, Nature Medicine.
[21] Philippe Leboulch,et al. Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2 , 2003, Nature Medicine.
[22] G. Vrensen,et al. Vascular endothelial growth factors and angiogenesis in eye disease , 2003, Progress in Retinal and Eye Research.
[23] Yihai Cao,et al. Placenta growth factor-1 antagonizes VEGF-induced angiogenesis and tumor growth by the formation of functionally inactive PlGF-1/VEGF heterodimers. , 2002, Cancer Cell.
[24] Xuri Li,et al. Novel VEGF family members: VEGF-B, VEGF-C and VEGF-D. , 2001, The international journal of biochemistry & cell biology.
[25] Xuri Li,et al. Isoform-specific Expression of VEGF-B in Normal Tissues and Tumors , 2001, Growth factors.
[26] N. Glazer,et al. Angiopoietin-1 protects the adult vasculature against plasma leakage , 2000, Nature Medicine.
[27] A. Milam,et al. Cancer-associated retinopathy. , 1999, Archives of ophthalmology.
[28] Patrick W. Faloon,et al. In vitro hematopoietic and endothelial potential of flk-1(-/-) embryonic stem cells and embryos. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[29] B R Johansson,et al. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. , 1997, Science.
[30] J. Folkman,et al. In vivo angiogenic activity and hypoxia induction of heterodimers of placenta growth factor/vascular endothelial growth factor. , 1996, The Journal of clinical investigation.
[31] K. Hirschi,et al. Pericytes in the microvasculature. , 1996, Cardiovascular research.
[32] J. Flanagan,et al. Heterodimers of Placenta Growth Factor/Vascular Endothelial Growth Factor , 1996, The Journal of Biological Chemistry.
[33] J. Stone,et al. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity , 1995, Nature Medicine.
[34] A. Roth,et al. Cancer-associated retinopathy (CAR syndrome) with antibodies reacting with retinal, optic-nerve, and cancer cells. , 1989, The New England journal of medicine.
[35] H. Dvorak,et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. , 1983, Science.
[36] S. Buzney,et al. Retinal capillaries: proliferation of mural cells in vitro , 1975, Science.
[37] Emmett T. Cunningham,et al. VEGF INHIBITION STUDY IN OCULAR NEOVASCULARIZATION CLINICAL TRIAL GROUP. PEGAPTANIB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2004 .
[38] A. Luttun,et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1 , 2002, Nature Medicine.
[39] H. Wilhelm,et al. [Carcinoma-associated retinopathy: a review with clinical examples]. , 2000, Klinische Monatsblatter fur Augenheilkunde.
[40] H. Wilhelm,et al. Karzinomassoziierte Retinopathie: Eine Übersicht mit klinischen Beispielen , 2000 .
[41] P. De Potter,et al. Ocular manifestations of cancer. , 1998, Current opinion in ophthalmology.